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“Not everything that can be counted counts. Not everything that counts can 
be counted.” 
William Bruce Cameron - A Casual Introduction to 
Sociological Thinking, 1963 
 
 
“Without data, you're just another person with an opinion.”  
W. Edwards Deming 
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ABSTRACT 
Background: Options for following up primary care at the regional level have 
increased in Sweden, partly as a result of a national reform in 2009. In Region 
Västra Götaland (VGR) this was the starting point for a quality initiative with 
about 100 indicators, using extensive healthcare registers.  
Aim: To perform a register-based evaluation of aspects on chronic disease 
management in primary care after the primary care reform in VGR. 
Patients and methods: The four studies were based on individual patient data 
from national and regional health data and quality registers.  
In Studies I and II, effects of pay for performance were analysed for patients 
and medical data in a quality register, as well as the association of inappropriate 
medications with the tendency to code for medication reviews. Results: Paying 
for data entry led to increased coverage, completeness and reliability. Paying 
for medication review coding was not associated with a greater reduction of 
inappropriate medications at highly reimbursed primary care centres than at 
others.  
In Study III, visit patterns at primary care centres in relation to blood pressure 
target achievement for patients with hypertension were studied. Results: 
Current care for hypertension was based mainly on appointments with 
physicians. Patients at primary care centres with more appointments with 
nurses than physicians reached blood pressure targets to a greater extent. 
In Study IV, adherence to guidelines and the potential of improvement for 
lipid-lowering therapy in patients with established coronary heart disease were 
studied. Results: Fewer than 20% of patients reached the current target for 
LDL cholesterol, and estimates based on a risk model showed that improved 
treatment could substantially reduce the number of future cardiovascular 
events. 
 
Conclusion: Individual-based regional data from healthcare and quality 
registers offer comprehensive sources of analysis of clinical practice, effects 
of reimbursement systems and guideline adherence for large groups of primary 
care patients. 
Keywords: cardiovascular diseases, diabetes, elderly, healthcare quality 
assurance, hypertension, incentive, nurses, pay for performance, potentially 
inappropriate medication list, primary health care, secondary prevention, 
statins, Sweden, quality indicators 
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SAMMANFATTNING PÅ SVENSKA 
Våra vårdcentraler/hälsocentraler är navet i svensk sjukvård. Det är där de allra 
flesta patienter tas om hand gällande allt från oro för sjukdom, råd kring enkla 
självläkande tillstånd, akuta sjukdomar och till patienter med kroniska 
sjukdomar samt svårt multisjuka. Här sköts allt från hälsokontroller av nyfödda 
barn till vård i livets slutskede på våra äldreboenden.  
För att säkra kvaliteten på vården behöver vi registrera och mäta en del av det 
vi gör för att med hjälp av resultaten kunna bedriva utvecklingsarbete till nytta 
för patienterna och därmed också öka jämlikheten i vården. I samband med 
vårdvalsreformen 2009 i primärvården i Västra Götalandsregionen 
strukturerades insamlingen av data från vårdcentralernas journalsystem vilket 
har medfört tillgång till stora mängder information som ligger till grund för 
den ekonomiska ersättningen till vårdcentralerna. Det är dock inte lätt att 
bedöma kvaliteten utifrån denna information då det finns många felkällor vid 
registrering och tolkning av data. Allt som utgör kvalitet kan inte mätas och 
det som kan mätas är inte alltid till nytta. Det finns dock ett antal 
kvalitetsregister i Sverige där data från vårdcentraler och annan vård samlats 
och som visats vara till nytta för ökad kunskap och utveckling av vården om 
den bearbetas och tolkas på ett strukturerat sätt. 
I studierna i denna doktorsavhandling har data från flera av dessa register 
använts för att analysera hur registrering av olika mått på vården rörande 
kroniska sjukdomar i primärvården i Västra Götalandsregionen har påverkats 
av vårdvalsreformen. Olika kvalitetsaspekter belyses också med hjälp av data 
från registren.  
Det kan kännas intuitivt tilltalande att stimulera önskvärda åtgärder eller 
resultat inom vården med pengar och därmed få mer av det som ökar nyttan 
för patienterna. Sådana ekonomiska incitament används och har använts i 
primärvården i syfte att förbättra vården. Detta leder dock inte alltid i den 
riktning som var tanken och i värsta fall till och med åt helt fel håll. I en av 
studierna visas att pengar kopplade till medicinska mål såsom blodtryck kan 
leda till att man börjar registrera annorlunda än man gjorde innan. Även om 
resultaten pekar mot en faktisk sänkning av blodtrycket så kan sådana effekter 
på registreringsbeteendet leda till mindre tillförlitliga data. En positiv effekt av 
att betala för registrering är att registreringen ökar och ju mindre data som 
fattas desto mer användbara blir registren. Ett annat incitament har varit att 
ersätta den specifika åtgärden att registrera en kod för att 
läkemedelsgenomgång har genomförts. Detta i syfte att våra äldre ska ha en 
 
mer adekvat läkemedelsbehandling. Vi har inte kunnat visa att 
läkemedelsbehandlingen förbättras vid de vårdcentraler som får mest pengar 
på grund av många koder jämfört med de vårdcentraler som inte kodar i samma 
omfattning.  
Andra sätt att försöka förbättra vården kan vara att strukturera den, speciellt 
för de kroniska folksjukdomarna. För till exempel diabetesvården krävs att 
varje vårdcentral i regionen har en diabetes-sjuksköterska. Detta tillsammans 
med uppföljning av mål-värden för diabetesvård har ökat kvalitén på vården i 
Sverige jämfört med andra länder. Motsvarande organisation finns inte för till 
exempel högt blodtryck. I en av studierna visas att vid de vårdcentraler där 
vården baseras på fler besök till sjuksköterska än till läkare har patienterna 
större chans att nå målblodtrycket. En förklaring kan vara att en förskjutning 
av uppgifter från läkare till sjuksköterska ofta sker med tydliga strukturerade 
rutiner för hur de berörda patienterna ska tas om hand samt att mer tid avsätts 
för dessa patienter och därmed ökas sannolikheten att riktlinjer följs.  
Riktlinjer för kroniska sjukdomstillstånd kan ta lång tid att introducera i den 
dagliga vården på vårdcentralerna. Vi har visat att det finns stor 
förbättringspotential i omhändertagandet av patienter som har 
kranskärlssjukdom. Alltför få har en tillräckligt bra blodfettssänkande 
behandling och om fler skulle få det skulle färre insjukna i en ny hjärtinfarkt 
eller i stroke.  
Sammanfattningsvis är det viktigt att fortsätta att mäta och utvärdera vården 
men vi måste vara medvetna om begränsningarna som finns inbyggda i 
mätandet. Dessa begränsningar skulle kunna illustreras av några engelska 
begrepp och citat:  
• ”The streetligtht effect” eller ”low-hanging fruits” – att vi 
letar efter saker där det är lättast att hitta dem eller vi väljer 
att mäta det som lätt går att mäta 
• ”Hitting the target but missing the point” – att uppsatta mål 
nås i form av registrerade koder till exempel men den önskade 
effekten uteblir  
Granskning och kontroll av det arbete som utförs tar allt mer plats på bekostnad 
av att utföra själva arbetet. Istället för att ständigt försöka hitta fler sätt att mäta 
och kontrollera verksamheten bör man också ha tilltro till personalens vilja att 
göra gott och skapa en arbetsmiljö där det finns utrymme att utvärdera sina 
egna resultat och utifrån dessa skapa strukturer och arbetssätt i syfte att hjälpa 
patienterna på bästa sätt. 
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 INTRODUCTION 
Quality is, depending on the area of interest, difficult or impossible to define 
and measure. The WHO definition of quality of care is “the extent to which 
health care services provided to individuals and patient populations improve 
desired health outcomes”.  
This thesis does not attempt to evaluate quality of primary care as a whole, 
only a few important aspects after a national reform in Sweden 2009. The 
reform was accompanied by a search for indicators to monitor and analyse the 
performance of primary care centres. This thesis deals with quantitatively 
important areas in which relevant results can be directly translated to clinical 
practice.  
PRIMARY CARE AND THE REFORM 
SWEDEN 
Swedish primary care differs in important ways from specialised care. 
Specialised care follows patients with specific diseases, typically for a limited 
period of time. Primary care follows patients with varying conditions and 
diseases for long periods of time [1]. The definition of primary care and its 
scope varies between countries and regions, but the Organization for Economic 
Co-operation and Development (OECD) has identified some common 
features: first-line care, provided in the proximity of the patient, patient-
focused as opposed to specialised care that has a disease or organ focus, broad 
in its context and a coordinator of the patients total care needs [2]. The 
importance of primary care for both initial assessment and chronic disease 
management is well-known [3-5]. More than 60 % of the 68 million medical 
appointments in Sweden every year are at primary care centres (PCCs) [6]. 
Swedish primary care is structured in 21 different regions. Their management, 
regulation and compensation systems are based on national laws including the 
Health and Medical Services Act (Hälso- och sjukvårdslagen 2017:30), Patient 
Act (Patientlagen 2014:821) and Patient Data Act (Patientdatalagen 2008:355). 
All regions offer primary care within a publicly financed system including both 
public and private providers. Approximately 43% of PCCs are privately run 
[7]. Healthcare expenditures in Sweden are funded chiefly (80%) by tax 
revenue [8].  
1 
 
Largely due to long-term accessibility problems, a primary care reform was 
launched in 2009 [9]. The government introduced a relatively deregulated 
market model by which compensation is associated with the individual patient. 
The legislation mandated new primary care systems with free choice of 
healthcare provider by 1 January 2010 (Lag om valfrihetssystem 2008:962) 
[10]. The systemic change was based on a model that included freedom of 
establishment as well [11, 12]. The reform also involved regional follow-up of 
PCC performance in order to ensure fair allocation among them. 
REGION VÄSTRA GÖTALAND (VGR) 
The primary care reform was launched in VGR on 1 October 2009. It was the 
starting point for an extensive regional quality initiative.  
VGR is located in south-west Sweden. The region is mixed urban and rural 
with approximately 1.7 million inhabitants (2011, 17% of the national 
population). Gothenburg, the second largest city in Sweden with close to 600, 
000 inhabitants is there. About three-fourths of the population lives in medium-
sized to large urban areas. Approximately 200 PCCs operate there in the wake 
of the reform, as opposed to 140 earlier. Roughly 47% are privately run.  
Following the reform, significant resources were devoted to development of 
an extensive follow-up system based largely on register data. The aim was to 
combine various sources to yield both statistical information and quality 
measures at the local level, as well as analysis and follow-up at the regional 
level. Starting in 2011, a total of 140 indicators were implemented and 
published online, including patient selection, specific chronic diseases, drug 
use, patient satisfaction, drug treatment of the elderly etc. [13]. Among the 
sources were drug prescription data, quality registers and the regional patient 
administrative database. 
Approximately 80 % of a PCC’s total revenue is based on capitation derived 
from age, sex (50%) and disease burden i.e. diagnoses (50%) [12, 14]. As in 
other regions, pay for performance (P4P) linked to a number of indicators was 
used enthusiastically. The total P4P payment was 3% of total revenue, the 
initial intention was to raise it to 10%. The current P4P is approximately 4% 
maximum. Payment is also based on geography and socioeconomic status 
according to the Care Need Index (CNI), compensation for interpreters and 
other separate commitments.  
The regional quality follow-up system introduced in VGR is extensive but has 
not yet been fully studied or evaluated. The system was made possible by large-
scale national and regional healthcare registers. 
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 REGISTERS 
Sweden has a long tradition of health data registers as well as quality registers,  
all based on the unique personal identity number [15]. A register may include 
information about either the total population or a particular cohort. Data can 
be used for research after approval by an ethical review board. Following is an 
overview of Swedish registers relevant to this thesis. Details about registers 
used in the thesis are presented in the methods section. 
POPULATION REGISTERS 
Population registers reflect demographics. The Population Register 
(Folkbokföringsregistret) kept by the Swedish Tax Agency (Skatteverket) and 
the Total Population Register (Registret över totalbefolkningen) kept by 
Statistics Sweden (Statistiska centralbyrån, SCB) describe the population with 
data on birth, marital status, family, migration, death and other circumstances 
[16]. The Tax Agency reports data to the Total Population Register, which is 
the primary source of demographic data for research purposes.  
NATIONAL HEALTH DATA REGISTERS 
National health data registers are kept by the Swedish National Board of Health 
and Welfare (Socialstyrelsen). They are governed by the Health Data Act (Lag 
om hälsodataregister 1998:543). Among them are the National Patient Register 
(NPR), Prescribed Drug Register and Cause of Death Register. Healthcare 
providers must report to these registers. 
The NPR can be used for statistics, evaluation, quality assurance and research. 
Data include hospital and specialised healthcare. Collection of individual 
patient data from primary care is, however, not permitted by the current 
legislation (Förordning om patientregister hos Socialstyrelsen 2001:707). The 
National Board of Health and Welfare has proposed a legislative amendment 
[17].  
REGIONAL HEALTHCARE DATABASES 
As opposed to the NPR, regions often collect individual data from primary care 
in their databases. These registers are similar to the NPR and include primary 
care details as well.  
QUALITY REGISTERS 
National (and regional) quality registers are subject to separate regulations. 
Since the 1970s, the national quality registers have been developed by 
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healthcare professionals for internal quality assurance and improvement of 
clinical practice [18]. There are over 100 national quality registers [19, 20]. A 
quality register is an automated, structured collection of personal data for 
systematic and continuous quality assurance and improvement. They are 
governed by the Patient Data Act (Patientdatalagen 2008:355). They serve a 
selected patient population based on diagnosis or treatment and collect 
individual patient data from different providers in one common database with 
the aim of improving care. This structure makes the registers highly suitable 
for comparative analyses and research. As opposed to national health data 
registers, patients may opt out. They must be informed prior to entry of their 
data.   
REGISTERS IN PRIMARY CARE 
Contrary to the situation for specialised care, entry of primary care data is 
fragmentised due to legislation and varying regional interpretation [21]. Since 
individual primary care data cannot be obtained on a national basis, such 
analysis is performed only at the regional level. National analysis can be 
conducted only by researchers after a separate applications to each region.  
Due to the virtually total absence of national individual primary care data, an 
initiative on behalf of the National Board of Health and Welfare started in 2000 
[22].  The conclusion was that national coordination was possible but would 
require structured electronic health records. Meanwhile, regional projects were 
under way. In 2010, the Primary Care Quality (PrimärvårdsKvalitet) initiative 
was taken by the Swedish Organisation for Primary Care Physicians with the 
aim of generating national, regional and local data to ensure continuous 
improvement. Specific quality indicators were developed. Primary Care 
Quality is chiefly a tool for follow-up and improvement based on local 
individual patient data. Due to privacy issues, there are still no nationwide 
individual patient data, only aggregate data on the PCC level are available.  
National quality registers are generally constructed and used for specialised 
care. But the vast majority of patients and most major chronic diseases are 
handled by primary care. With the exception of the National Diabetes Register 
(NDR), national quality registers have generally failed to receive widespread 
acceptance among primary care providers such that national and regional 
coverage is highly limited. The biggest obstacle is probably that manual data 
entry is the predominant approach. Given that primary care addresses a broad 
spectrum of conditions, the method is not feasible. 
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 The regional primary care register in Västra Götaland (QregPV) is the only one 
that was developed specifically for improvement in the area. Proceeding from 
data on major chronic diseases, its main purpose is to follow PCC guideline 
adherence with respect to hypertension or ischaemic heart disease.  
PRACTICAL ASPECTS OF REGISTER-BASED 
RESEARCH 
Sweden’s 12-digit personal identity number makes it possible to link data from 
all registers [15]. Approval by a regional ethical review board is a prerequisite 
to creating datasets that can be combined for use by researchers. A specific 
register is normally the basis for selecting a patient cohort. Particular data in 
the register are requested, including the time frame as well as exclusion and 
inclusion criteria and variables. If data from various registers are to be merged, 
a request must be sent to all of them. The original dataset is forwarded for 
construction of files and replacement of personal identity numbers by 
anonymous identifiers for each patient (pseudonymisation), see Figure 1. 
Negotiation between the various authorities determines who will perform 
pseudonymisation and, if requested, keep the code key. The code key is saved 
in a secure environment, most often at the National Board of Health and 
Welfare, for possible update during a period specified on the application to the 
ethical review board. The files from the various data sources are sent to the 
researchers, who link content based on the pseudonymous identity numbers.  
As for the analyses in this thesis, additional protection can be provided at the 
Centre of Registers in Gothenburg by means of Secure On-line Data Access 
(SODA) and remote access from local computers. Only researchers working 
on projects with ethical review board approval may use the remote service. The 
files of individual patient data cannot normally be downloaded to a local 
computer.   
A major advantage to using population databases and register-based data is that 
the study period has already passed [23]. Given such real-world data that are 
not entered for specific use, bias is also minimised. However, retrieval can take 
some time. Processing periods at the National Board of Health and Welfare 
may be several months, which must be considered when planning register-
based research. Nor can analysis begin until additional refinement has been 
performed. 
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POPULATION AND PATIENT INVOLVEMENT 
Participation in population and national health data registers is mandatory and 
patients are not involved in decisions concerning associated research. Before 
being included in a quality register, they must be informed and given the 
opportunity to opt out. They are normally told that data may be used for 
research purposes following approval by an ethical review board. The registers 
are transparent and typically post information about their purpose and use by 
researchers to a website. Patient advocacy groups must have representation on 
the steering committee before national funding can be obtained. Whether or 
not patients are to be informed and given the opportunity to opt out of register-
based research is determined by the ethical review board. When the study 
population is large, individual patient consent is impractical. However, 
approval by an ethical review board, including its lay members, is mandatory.  
A 2017 report based on surveys and interviews found that the majority of the 
Swedish population is positive to the use of digital data in healthcare and 
research [24]. A Finnish study arrived at a similar conclusion [25]. The 
Research group 
PIN 
PIN 
Pseudonymous identity 
numbers 
PIN 
Figure 1. Schematic description of typical data transfer and links to create a patient file for 
research. Abbreviations: LISA: Statistics Sweden Longitudinal Database; NPR: National 
Patient Register; PIN: personal identity number; SCB: Statistics Sweden; Vega: regional 
administrative healthcare database. 
SCB 
The National Board of 
Health and Welfare 
Data source (quality 
register, Vega) 
Cause of Death 
Register 
Prescribed Drug 
Register 
Total Population 
Register 
LISA 
 
NPR 
 
Research file with 
added information 
for each individual 
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 respondents were largely satisfied with methods that are broader than 
individual informed consent. Awareness about register-based research was low 
among European stroke survivors [26]. Young patients with high educational 
levels wanted above all to be more involved. 
INTERPRETATION OF DATA 
The growing availability of Swedish healthcare data has created a demand for 
transparency and reporting to public servants, media and the general 
population. The ability to perform comparisons and make decisions is 
intuitively appealing. This transparency has been provided by Open 
Comparisons (Öppna jämförelser) since 2005 with regional feedback [27]. 
Since 2015 a website entitled Healthcare in figures (Vården i siffror) has 
offered similar comparisons [6]. Open comparisons can serve as incentives and 
have been shown to grow in importance over time among British PCCs [28, 
29]. Accessible data are key to fruitful discussion and the potential for more 
targeted quality improvement [30]. While transparency is worthwhile and 
well-intended, accompanying problems need to be addressed.   
A critical analysis has suggested that true transparency is not about publishing 
available data but an active creative process that proceeds from specific 
methods [31]. The problems arise from the complicated nature of the 
healthcare system, which is amenable to independent assessments by experts 
only. Presenting data without adequate interpretation may give only an illusion 
of transparency.  
A practice can be characterised by means of overall (normative) and 
technological (concrete) elements [32]. Striving for transparency can measure 
only a limited number of parameters even while trying to capture a broader 
context. Unintended consequences for the organisation and its outcomes may 
arise. New motivational structures emerge as the focus shifts from proper care 
to compliance with the process, including time-consuming administrative 
tasks. Performance measurements is not a neutral activity. Other concerns fall 
by the wayside. It was concluded that “The audit society is a symptom of the 
times …” and that observation is highly rewarded and considered more 
important than actual practice  [32]. 
Comparisons between care units should be interpreted with caution as a 
guidepost and basis for further dialogue [33, 34]. The challenges posed by 
access to register data by purchasers of healthcare, representatives of the public 
and media and the risk of misinterpretation was recognised early [18]. Experts 
understood that quality registers should be used critically and not for 
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comparison purposes. The importance of medical expertise when interpreting 
and applying data at both the national and local level was underscored. 
Noticeable is that many PCCs in the region have no physicians in any leading 
position. 
A central question is whether healthcare quality can be measured by figures, 
particularly in relation to transparency, open comparisons, follow-up and 
reimbursement as described in the report Making Care Even Better (Ännu 
bättre vård) by Bo Bergman [33]. Many aspects of healthcare are difficult and 
tricky to measure. Not all that can be measured, on the other hand, is relevant. 
Variations between measurements and care units must be taken into 
consideration. If care units are compared in accordance with a specific 
variable, the results will inevitably vary. The most interesting possible finding 
is that the variation is higher than may be expected on a normal or random 
basis. Thus, trends over time are highly revealing. Ordinary statistical 
measures suffer from limitations in such comparisons. For instance, the 
proportion of patients with blood pressure (BP) below a specific target can be 
misleading since the same value is compatible with both a small dispersion 
with results just above the target or a large dispersion with many results well 
above the target. In the first case the PCC might have prioritised patients with 
the poorest BP, and in the second case those who had almost achieved the 
target already. Quality care is hard both to define and to measure.  
The problems described above call into question all measurements designed to 
compare quality. But too much scepticism about comparisons could side-track 
important information and the ability to address key healthcare issues. The 
studies in this thesis highlight data use that fails to provide increased quality 
as well as possibilities to improve transparency by interpreting complex data. 
AREAS OF FOCUS IN THE THESIS 
The studies in this thesis have focused on three areas: 
• Financial incentives to improve quality of care 
• The impact of organisation on quality of care  
• The gap between guidelines and clinical practice  
After the primary care reform, the majority of quality indicators, several of 
which are linked to financial incentives, address patients with diabetes, 
hypertension, coronary heart disease (CHD) and other chronic conditions, as 
well as multi-pharmacy in the elderly. The incentives have been the subject of 
public debate; this thesis targets two particular areas. Although incentive 
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 schemes for treatment of chronic disease have attempted to improve quality, 
adherence to guidelines in regional follow-up systems has been poor. For that 
reason, other aspects of chronic disease in primary care were also studied. One 
of them was nurse-based care as a way of better controlling BP in cases of 
hypertension. Another aspect was adherence to lipid-lowering treatment 
guidelines and the potential reduction of cardiovascular events among those 
with established CHD.  
FINANCICAL INCENTIVES  
The launch of the primary care reform in VGR was accompanied by 
enthusiasm about financial incentives to improve quality [12]. A brief history 
of national healthcare systems is useful in this connection. 
LOOKING BACK 
National healthcare systems have evolved through three phases: 1) equality 
and accessibility by everyone; 2) cost containment; 3) performance and 
efficiency enabled by register data [35, 36]. In the wake of economic growth, 
financing of the healthcare system was only a minor problem during the 1960s 
and 1970s. Dissatisfaction with rising costs of healthcare in the 1980s led to 
framework budgets. More decentralised decision-making was also targeted. In 
the late 1980s and 1990s, low productivity encouraged a greater market 
orientation such that many regions introduced client and provider 
organisations. Providers were remunerated on the basis of various productivity 
indicators. The third phase started in the 2000s with increased focus on quality 
and results. P4P was inspired by the experiences of both the United States and 
the National Health Services in the UK. The reform was the opening shot for 
use of P4P in primary care. The independent regional structure of separate data 
management and follow up systems resulted in as many reimbursement 
schemes.  
PAYMENT PRINCIPLES 
Payment principles are either fixed or variable. Fixed payments may be based 
on framework budgets for which compensation proceeds from resource 
consumption. Capitation based on the population may also be viewed as fixed, 
although payment in a system that includes freedom to choose PCC varies with 
the number of patients. Capitation may be based on age and sex, or more 
elaborately on adjusted clinical groups (ACG) that reflect diagnoses in medical 
charts, as an indicator of disease burden. Someone with diabetes or another 
chronic disease commands higher payment than a healthy person of the same 
age and sex.  
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Variable payments are incentives linked to quality of care and similar 
parameters. They may be process or outcome measures, such as BP entry or 
the percentage of patients with BP below a certain target [35, 37]. 
Classification of care measures (KVÅ) codes are also process-oriented. 
Outcome measures can be broken down into intermediary (BP target etc.) and 
final (cardiovascular event, death etc.). Another kind of variable payment is 
fee-for-service.  
PAY FOR PERFORMANCE (P4P) 
P4P, which links incentives to desired activities or goal achievement, has 
become integral to many healthcare systems over the past few decades. P4P 
can be associated with process, outcome and structural measures, such as 
employing a diabetes nurse at the PCC [37]. National quality registers, 
originally developed by healthcare professionals for internal quality assurance 
purposes, have more recently served as the basis for financial incentives, such 
as P4P coupled to process and outcome measures. 
The various approaches to targeting payment have various advantages and 
disadvantages. Studies have found improved register entry and results for 
clinically important indicators such as BP among patients with diabetes [38, 
39]. Evidence that P4P has a sustained positive effect is nevertheless weak and 
inconclusive [40-45]. Clinical practice may change and process measures 
improve short-term, but the impact on intermediate health outcomes is more 
doubtful.  
Financial incentives may even be counterproductive. The underlying 
assumption is that targets change behaviour in the desired direction and that 
abuse of the system is uncommon. Since quality of care is difficult to define, 
what to measure and reimburse for is a hazy area [46]. The risk arises that 
healthcare will be channelled in a non-optimal direction due to a focus on 
quality outcome measures that are low-hanging fruits as targets for payment 
[47, 48]. The indicators, like coding for various interventions, that can be 
gauged are often proxies for actual outcomes. You get what you ask for, and 
you may miss the forest for the trees by attaining the target but not the desired 
effect.  
Defined targets always relate to a subset of total performance [49]. Non-
targeted areas may be assigned lesser importance [50, 51]. Patients for whom 
target attainment is difficult may be ignored  [52]. They might just happen to 
be the people who are in most need of medical attention. 
10 
 
 External spurs like P4P may undermine the intrinsic motivation of 
professionals to do a good job [53]. New data entry requirements may take 
time away from patient care. If requested information, such as codes for 
follow-up and monitoring, is not regarded as medically relevant, the negative 
impact may be even greater.  
Moving targets to accommodate results is another potential hazard. The 
incentive to perform as well as possible disappears [49]. “Ratchet” and 
“threshold” effects have also been highlighted. The “ratchet effect” refers to 
resting on one’s laurels once a target has been attained [50]. The “threshold 
effect” refers to the tendency of results to coalesce around the target from both 
above and below. Superior performance may fall by the wayside.  
ORGANISATION – NURSE-BASED CARE 
Financial incentives introduced after the primary care reform seek to ensure 
quality by means of stricter adherence to guidelines for chronic disease. In 
addition to patient or physician factors, organisational parameters are potential 
facilitators or obstacles to risk control [54]. For example, nurse-based and team 
care are proven vehicles of improvement [54, 55]. The PCCs in VGR have 
been required to employ a diabetes nurse ever since the primary care reform 
went into effect [56]. Hypertension or CHD are not subject to similar 
organisational demands. The latest European guidelines for prevention of 
cardiovascular disease (CVD) recommend teamwork to improve BP control as 
well as long-term management of hypertension, and stress the role of nurses 
[57]. 
A WHO-report identifies task shifting as a means of strengthening staff  and 
improving patient access [58]. The report presents global recommendations 
and guidelines for HIV while making it clear that other essential health services 
could benefit from them as well. It conclude that nurses and professionals can 
safely and effectively perform clinical tasks that have traditionally been the 
purview of physicians.  
Such an approach may be a pragmatic approach to addressing physician 
shortages [59] on the basis of structured protocols [60]. Maintained quality is 
vital, and the evidence suggests that the approach, in both primary and 
secondary prevention, may be superior to standard care [61, 62]. Task shifting 
may include prescriptions, treatment, referrals etc. Some countries have come 
further in this respect than Sweden [59]. 
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ADHERENCE TO GUIDELINES 
Notwithstanding financial incentives for stricter adherence to guidelines 
concerning the treatment of risk factors associated with chronic disease, there 
is still room for improvement. When it comes to secondary prevention of CVD 
in primary care in VGR, only 20% of patients with a CHD diagnosis attain the 
low density lipoprotein cholesterol (LDL-C) target of <1.8 mmol/L [63, 64]. 
The percentage of patients with a CHD diagnosis who attain the recommended 
target for LDL-C in secondary prevention is increasing but is still low, as in 
other countries [65, 66].  
Recent evidence shows an almost linear relationship between LDL-C level and 
risk of CVD [67]. Lowering of LDL-C by means of statin treatment effectively 
reduces risk of CVD recurrence [68]. The same is true of the elderly [69]. Non-
adherence to secondary prevention medication including statins, is associated 
with an increased risk of CVD events and all-cause mortality [70].  
Adherence is the responsibility of both the physician and the patient. The 
physician must be knowledgeable and receptive to current guidelines while the 
patient must be properly informed and willing to follow recommendations [54, 
71]. Attitudes have an impact in both directions. Adherence over time is a 
particular challenge. Non-adherence may be intentional due to 
contraindications etc., or unintentional due to ignorance or lack of awareness 
[72]. Staffing, routines (structured, team-based care, etc.) and other 
organisational factors also influence adherence to guidelines [73-76]. Clinical 
inertia plays a part as well [77].  
SUMMARY 
Primary care is essential to the care and prevention of chronic diseases. Many 
patients that are at risk for serious complications are taken care of. After the 
primary care reform, extensive data are available at the regional level. 
Register-based follow-up of has great potential for quality assessment but 
careful interpretation is required. Primary care research with high clinical 
relevance is needed. This thesis has targeted important aspects of quality 
following the primary care reform in 2009. 
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 AIM 
The general aim of this thesis was to perform a register-based evaluation of 
various aspects of chronic disease management after the launch of an extensive 
register-based primary care quality initiative in primary care in VGR. 
Study I 
The aim was to, proceeding from NDR data, assess the effects of a payment 
programme for primary care, on register entry practices on behalf of 
individuals with type 2 diabetes. Register data quality and comparability 
were studied by evaluating characteristics of new patients and data entered 
after introduction of the P4P payment programme.  
Study II  
The aim was to determine whether the adoption of a P4P process measure 
linked to medication review coding had been associated with an increase in 
the volume of reviews and an improvement in drug treatment among elderly 
primary care patients based on a series of national indicators. 
Study III 
The aim was to examine visit patterns as a measure of how care is structured 
at the PCC level based on real-life data, as well as whether nurse-based 
approaches were linked to better BP control in primary care patients with 
hypertension and no complications. 
Study IV 
The aim was to describe adherence to guidelines concerning secondary 
prevention lipid-lowering treatment and estimate the potential reduction in 
CVD events within 5 years if all relevant patients improved in that regard. 
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 PATIENTS AND METHODS 
SUMMARY OF METHODS 
This thesis is based on four studies, see Table 1. All of them were register-
based observational studies based on individual patient data and research 
questions stemming from regional monitoring system observations.  
Table 1. Summary of methods used in the studies 
Study I II III IV 
Design Repeated 
cross-
sectional  
with a 
reference 
group 
Repeated 
cross-
sectional 
Cross-
sectional 
Cross-
sectional 
/risk 
estimation 
modelling 
Level of 
analysis 
Patient Patient and 
PCC 
Patient and 
PCC 
Patient 
Period 2010-2011  2009-2013 2015 2015 
Sources 
of data 
NDR Vega 
Prescribed 
Drug 
Register 
Swedish 
Population 
Register 
QregPV 
Vega 
National 
Patient 
Register 
Prescribed 
Drug 
Register 
LISA 
QregPV 
Vega 
National 
Patient 
Register 
Prescribed 
Drug 
Register 
Cause of 
Death 
Register 
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Study I II III IV 
Study 
group 
Primary care 
patients in 
the NDR 
(age 18-79) 
Patients age 
75 or older 
with at least 
one PCC 
appointment 
during the  
year 
Patients age 
40-80 in the 
QregPV with 
hypertension 
and available 
systolic BP  
Patients in 
the QregPV 
with a 
previous 
diagnosis of 
CHD (I20-
I25) 
Total 
number 
of 
patients 
84,053 181,210 
~ 95,000 per 
year 
88,945 86,206 
Exposure Region 
VGR/Skåne 
(financial 
incentive 
programme) 
PCC groups 
1-3 (based on 
percentage of 
patients with 
a code for 
medication 
review) 
PCC visit 
patterns 
*Atorvastatin 
40/80 mg or 
LDL-C-target 
(< 1.8 
mmol/L) 
Main 
outcome 
variables 
Entry, levels 
and target 
achievement 
for HbA1c, 
BP and LDL-
C 
Percentage 
of PCC 
patients 
receiving 
inappropriate 
drugs 
according to 
national 
indicators 
OR for the 
individual to 
attain BP ≤ 
140/90 
mmHg 
*Reduction 
in number of 
CVD events 
over 5 years 
Co-
variates 
Age, sex, 
diabetes 
duration 
Age, sex, 
ACG weight 
Age, sex 
BMI, 
smoking, 
socioeconom
ic status, 
number of 
drugs, 
Age, sex, 
diabetes, 
comorbidity, 
medications 
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 Study I II III IV 
medications, 
appointments 
Handling 
of 
missing 
data 
Deletion of 
observations 
with missing 
data 
depending on 
the analysis 
No missing 
data 
Multiple 
imputation 
Use of 
available 
variables in 
the risk 
model 
/deletion of 
observations 
with missing 
data in the 
prediction 
model 
Method Student’s t-
test, chi-
square, 
generalised 
linear model 
Generalised 
linear mixed 
model for 
repeated 
measure-
ments 
Multi-level 
generalised 
linear mixed 
model 
Cox 
proportional 
hazard 
regression 
*Study IV did not look at the effect of exposure on an outcome.  
Abbreviations: ACG: adjusted clinical groups; BMI: body mass index; BP: blood pressure; CHD: coronary 
heart disease; CVD: cardiovascular disease; HbA1c: glycated haemoglobin; LDL-C: low density lipoprotein 
cholesterol; LISA: Statistics Sweden Longitudinal Database; LOCF: last observation carried forward; NDR: 
National Diabetes Register; OR: odds ratio; PCC: primary care centre; QregPV: regional primary care 
register; SBP: systolic blood pressure; Vega: regional administrative healthcare database 
SOURCES OF DATA 
The studies proceeded from national patient data registers and databases, as 
well as quality registers, depending on the research question to be addressed.  
The following registers were used:  
NATIONAL DIABETES REGISTER (NDR) 
The NDR was launched in 1996 by the Swedish Society for Diabetology as a 
nationwide, population-based vehicle for improvement of diabetes care quality 
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[78]. The register contains individual patient data concerning laboratory 
analyses, clinical characteristics and complications. Separate primary and 
secondary care units report to the register either online or by means of clinical 
record databases. The register covered approximately 85% of patients with 
diabetes in 2011 [79] and an estimated 96.5% today [80]. Although reporting 
to the NDR is not mandatory in VGR, all PCCs do so given that a diabetes 
nurse is required and all follow-up data on patients with diabetes must be sent 
to the region. 
REGIONAL ADMINISTRATIVE HEALTHCARE 
DATABASE (VEGA) 
Vega, which was set up in 2000, covers all healthcare contacts in the VGR [21, 
81]. The database also includes information about residence, age, sex, PCC 
and diagnostic codes according to the International Classification of Diseases 
(ICD). The diagnoses are entered in the electronic patient chart along with a 
healthcare contact. All care units, including PCCs, must report to Vega. 
Reimbursement to PCCs for capitation and disease burden is based on data 
from the database. VGR forwards information from Vega about hospital and 
other specialised care contacts to the NPR.  
REGIONAL PRIMARY CARE REGISTER (QREGPV) 
The QregPV started in 2006 as a professional initiative (Allmänmedicinska 
Sektorsrådets Arbetsgrupp för Kvalitet, ASAK) [64]. QregPV contains data 
about five major chronic conditions; diabetes, CHD, hypertension, asthma and 
chronic obstructive pulmonary disease (COPD). Its primary focus nowadays is 
PCC adherence to guidelines for hypertension and CHD [63]. For patients with 
diabetes, the NDR serves mostly as a source of data. QregPV initially obtained 
information from publically owned PCCs only. After the healthcare reform in 
VGR 2009, privately owned PCCs were also included and it was converted to 
a quality register. Since 2010, QregPV has been managed by the Centre of 
Registers in VGR. The variables are BP, glycated haemoglobin (HbA1c), 
lipids, smoking, height, weight, girth and body mass index (BMI). PCCs report 
to QregPV on a monthly basis.  
PRESCRIBED DRUG REGISTER  
The Prescribed Drug Register contains information about all filled 
prescriptions since 1 July 2005. The Swedish eHealth Agency performs 
monthly quality checks before data is forwarded to the National Board of 
Health and Welfare [82, 83]. The register includes data about patient 
characteristics (age, sex, residence etc.), prescriber characteristics (profession, 
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 specialty, type of care etc.) and medication (date dispensed, formula, container 
size, dosage etc.). All medications are categorised according to the Anatomical 
Therapeutic Chemical  (ATC) classification system [84].  
NATIONAL PATIENT REGISTER (NPR) 
The NPR contains information about diagnoses and interventions at hospital 
since 1964. It became nationwide in 1987 and has included information from 
both public and private specialised care units outside hospital since [85]. 
Pursuant to current legislation, the register does not include any primary care 
information [17]. Diagnoses are categorised according to the ICD [86]. 
Healthcare providers have supplied data on a monthly basis since 2015 in view 
of a new code of statutes (SOSFS 2013:35). The Swedish National Inpatient 
Register which is part of the NPR, has almost complete coverage and was 
found to offer high validity for many diagnoses [87]. 
CAUSE OF DEATH REGISTER 
The Cause of Death Register contains official national statistics on all fatalities 
since 1961 [88]. The register is updated once a year. Since 2012, all deaths are 
included regardless of whether or not the individual was a Swedish citizen. The 
variables include date, age and cause of death according to the ICD [86]. 
POPULATION REGISTER 
The Population Register is kept by the Swedish Tax Agency with the aim of 
reflecting personal details, family relationships and composition of the 
Swedish population [16]. When first entered in the register, an individual is 
assigned a 10-digit personal identity number that has been in effect ever since 
1947 [15]. In 1991, the Tax Agency took over census responsibilities from the 
Church of Sweden. Life events such as births, marriages and deaths and also 
place of residence are continuously recorded.  
STATISTICS SWEDEN LONGITUDINAL DATABASE 
(LISA) 
Since 1990, LISA has contained data for individuals 16 or older who were 
entered in the population register as of 31 December for each year. LISA 
obtains information from several demographic registers concerning the labour 
market, educational and social sectors, including date of birth, marital status, 
schooling and income [89].  
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ETHICAL APPROVAL AND CONSIDERATION 
The Regional Ethical Review Board in Gothenburg has approved all studies in 
this thesis with the following reference numbers: 564-12 (Study I), 362-14, 
T080-15 (Study II), 1062-15 (Study III and IV). 
Ethical approval of register-based research is a balancing act between the 
benefits for public health and personal privacy. A patient can opt out of a 
quality register but not a demographic or health data register. Before being 
included in a quality register, the person is to be informed of that which can be 
done with written or oral information. Informed consent is not mandatory, and 
generally not feasible, in register-based research. Study populations may 
number in the tens of thousands and many of them will be dead once the study 
is conducted. Informed consent may result in selection bias. Since the studies 
include so many patients, the risk of violating personal privacy is very small. 
STATISTICS 
STUDY DESIGN 
Register-based studies are a mix of prospective and retrospective design [90]. 
Data are collected before subsequent studies have been planned, not chiefly for 
specific research. A register consists rather of a standardised information for a 
group of individuals. Patient selection, hypothesis generation etc. are the 
mostly retrospective. Data about exposure and outcome are often prospective. 
The studies in this thesis are observational and cross-sectional in the sense that 
the population and the exposure is defined at a point or interval of time. 
Patients were chosen on a particular date but additional information about them 
could be obtained before that.  
Both Studies I and II collected and compared data at different points in time 
but did not follow a cohort. The design was not longitudinal since patients were 
not the same at the different points in time. 
Studies I, II, III were modelled largely for explanatory rather than predictive 
purposes. The aim was to test for causal (rather association) hypotheses. Study 
IV designed a model for predictive purposes, primarily to compare number of 
events, not to anticipate their number as accurate as possible.  
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 MISSING DATA 
Missing data are common in register-based studies. If missing data are random, 
it may be safe to delete these particular cases, but that is not typically the 
situation. For example, LDL-C values may be missing mostly among older 
patients with multi-morbidity.  
These problems were dealt with in the included studies in the following ways: 
• Deletion 
o Observations (Study I) – using a subset of 
observations with complete data or using all possible 
patients in various analyses depending on the 
available data. Complete case analysis includes only 
patients for whom all variables are available. 
o Variables (Study IV) – choosing models that do not 
include variables with large quantities of missing 
data. 
• Imputation  
o Multiple imputation (Study III) is a way of replacing 
missing data with estimated values based on 
information available in the data set and taken from a 
distribution. The substitution is performed multiple 
times, generating a number of data sets whose results 
are pooled. This compensates for the uncertainty of 
the imputation.  
Before applying the techniques above, the data sets were completed as much 
as possible by means of last observation carried forward (LOCF). Most 
registers include information from every contact, several of which may ensure 
complete data. For instance BP can be entered at one point in time and body 
weight later on. 
CONFOUNDING 
A confounder affects both the predictor (independent) and outcome 
(dependent) variable. Confounding can cause bias which is important to be 
aware of even if the magnitude of the effect cannot be assessed. Age is a typical 
confounder that effects almost all predictors and outcomes.  
Register-based studies limit the confounders that can be accounted for to those 
that are accessible in the particular databases. For both ethical and practical 
reasons, it is rarely possible to collect other information concerning each 
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patient. Confounders were chosen, for the studies included, on the basis of 
clinical knowledge and available data.  
STATISTICAL METHODS 
DESCRIPTIVE STATISTICS 
Descriptive statistics were presented using the arithmetic mean and standard 
deviation for continuous variables, as well as frequencies and percentages for 
categorical variables.  
GROUP COMPARISONS 
Comparisons between groups of patients used Student’s t-test for continuous 
variables and χ2-test for categorical variables. Hypothesis tests had a two-sided 
alternative; a p-value < 0.05 was considered statistically significant. Odds 
ratios (OR) and estimates were presented with 95 % confidence intervals (CI).  
GENERALISED LINEAR MODELS 
Regression models examine the association between a dependent variable and 
one or more continuous independent variables. Analysis of variance (ANOVA) 
is used for categorical independent variables. ANOVA and regression models 
are mathematically similar. Analysis of covariance (ANCOVA) is a general 
linear model (combination of regression and ANOVA) that includes both 
continuous and categorical independent variables. The dependent variable is 
continuous in linear regression (and ANOVA).  
For binary dependent variables, logistic regression is used instead. In Poisson 
regression, the dependent variable is a count variable. Generalised linear 
models are flexible tools that allow for dependent variables with non-normal 
distribution through the use of link functions. These models can handle 
variables with binary, Poisson and other distributions. 
MIXED MODELS 
Mixed generalised linear models are used to capture correlations between 
observations, for example patients at the same PCC or repeated observations 
on the same patient, see Figure 2. A distribution of the dependent variable and 
a suitable link function, for example a binomial distribution with a logistic link 
function or a Poisson distribution with a log link function, must be chosen.  
 
22 
 
  
 
Mixed models include random and fixed factors. Random factors are measures 
of variance and fixed factors measures of association. The random factor is the 
variable for which we are not interested in the outcome related to it but want 
to take the influence of it into consideration and is defined as a distribution. 
PCC enrolment may be such a random factor when the aim is not to compare 
PCCs with each other. The fixed factors are the covariates adjusted for in the 
model and can be defined in levels/numbers, for example age and sex.  
SURVIVAL ANALYSIS 
Survival analysis examines the risk that an event will occur over time. 
Individuals are followed until an event (disease, death) is noted. Someone who 
does not experience an event during the period is referred to as censored, a 
form of missing data. In this thesis (Study IV), data is (right) censored due to 
end of follow-up or death.  
Cox proportional hazard is a regression model that analyses the association 
between survival time and selected independent variables (risk factors). The 
hazard function, i.e. the risk that an event will occur at a specified time, is 
conditional on being event-free until then. The cumulative hazard over time is 
subsequently modelled. The survival function is the likelihood of not having 
experienced an event within a specified time. Summing up the individual risks 
of an event yields the total number of individuals who are predicted to 
experience it. Estimates from the regression model are hazard ratios (HR) with 
a 95% confidence interval.  
The statistical analyses were performed using SPSS version 20.0 (SPSS Inc., 
Chicago), SAS version 9.4 (SAS Institute, Cary, NC) and R 3.4.0. 
PCC
Physician 1
Patient 1 Patient 2
Physician 2
Patient 3
Patient 1 Year 1 Year 2
Patient 2 Year 1 Year 2
Patient 3 Year 1 Year 2
Figure 2. Examples of multilevel mixed models. Abbreviations: PCC: Primary care center 
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STUDY I – P4P AND DATA ENTRY 
STUDY RATIONALE 
A new payment programme that was introduced in VGR on 1 January 2011 
included incentives linked to entry of patients and medical variables in NDR, 
as well as medical target attainment. Region Skåne was chosen as the reference 
because no such targets had been included in its payment scheme. The 
reference region is similar to VGR in terms of primary care organisation, 
including population choice, enrolment at PCCs, responsibility for 
expenditures and structure of the payment programme [12]. Both regions use 
a fixed payment approach for enrolment (capitation) at PCCs based on age, 
sex, diagnostic classification and socio-economic indicators. NDR patient 
entry was rewarded in both counties.  
After introduction of the P4P programme in VGR, up to 4% of the total income 
for a PCC, approximately one-quarter of which was accounted for by diabetes, 
was based on quality indicators [13]. PCC participation in the incentive 
programme was mandatory, and there was no system for excluding patients. 
The P4P programme in VGR rewarded NDR entry, as well as the percentage 
of patients with:  
• a value for HbA1c, BP, LDL-C, albuminuria and smoking 
• HbA1c < 52 mmol/mol 
• BP < 130/80 mmHg 
• LDL-C < 2.5 mmol/L 
STUDY POPULATION AND PERIOD 
Primary care patients age 18-79 in the NDR from 2008 to 2011 were included 
for both VGR and the reference region. Data for 2008-2009 were used to 
determine the patients or patient data that were new to the register in 2010-
2011 (not having been entered for the previous two years). Patients were 
included whether or not they were classified with type 1 or type 2 diabetes 
given that 97 % have type 2.  
STATISTICAL METHODS 
Comparisons were performed between both regions and years. The variables 
assessed were HbA1c, BP, LDL-C and the percentages of patients who reached 
the targets, as defined above. The percentages of patients with values for the 
above variables, as well as albuminuria and smoking, were also compared. 
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 The statistical significance tests were Student’s t-test for continuous variables 
and the χ2-test for categorical variables. For regression analyses, a generalised 
linear model and ANCOVA were used.  
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STUDY II – P4P AND PROCESS MEASURES 
STUDY RATIONALE 
VGR has used coding for medication reviews as a P4P quality indicator since 
2009 for patients age 75 and older. Payment has varied over the years. At the 
end of the study period (2013), financial compensation was granted and 
increased linearly if the percentage of these patients at the PCC, for whom a 
medication review had been entered within the past 12 months, was between 
30-60%. 
The medication review is an assessment of the patient’s medication list and 
should be performed at least once a year during a doctor’s appointment. 
Pharmacological treatment was assessed in accordance with the National 
Board of Health and Welfare indicators for appropriate drug treatment among 
the elderly [91, 92]. 
STUDY POPULATION AND PERIOD 
Annual data for 2009-2013 concerning patients age 75 and older with at least 
one PCC appointment and who were alive at the end of the year were extracted 
from Vega, see Figure 3. Only patients enrolled at the same PCC for the entire 
study period were included. The data included date of birth, sex, PCC, 
appointments, medication reviews and diagnoses. ACG weight was calculated 
from diagnoses as of 31 December as a proxy for morbidity. Data for 
medications and date of death were added from the Prescribed Drug Register 
and the Population Register.  
Vega (patient 
selection) 
Prescribed Drug 
Register 
Population 
Register 
Medications 
 
Deaths 
Figure 3. Register data for study II. Vega: regional administrative healthcare 
database 
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STATISTICAL METHODS 
The PCCs were broken down into three groups of equal size based on the 
lowest (1), middle (2) and highest (3) percentage of patients for whom a 
medication review was coded in 2013.  
The dependent variables (medication indicators and number of drugs) were 
modelled by means of a mixed generalised linear model with a compound 
symmetry matrix that captured correlations between observations of the same 
patient for the various years. A logistic link function and binomial distribution 
were used for binary outcomes (medication indicators) and a log link function 
with Poisson distribution for the number of drugs.  
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STUDY III – ORGANISATION – NURSE-BASED 
CARE 
STUDY RATIONALE 
More than 150,000 primary care patients with hypertension in VGR have 
individual data reported to the QregPV. Specialised nurses for diabetes and 
asthma/COPD are mandatory, but PCCs are free to structure their own 
hypertension care [13]. As presented in regional feedback systems, the 
proportion of patients reaching BP target is approximately 50% [64]. Structure 
and team changes with nurse-based care have proven efficient [93].  
STUDY POPULATION AND PERIOD 
Patients age 40 – 79 with hypertension and no concomitant disease as reported 
in QregPV on 31 December 2015 were included, see Figure 4. Individuals 
without PCC enrolment or at PCCs with less than 150 eligible patients were 
excluded since visit patterns might be too random and less stable over time. 
Additional information at the individual level was added from Vega, the 
Prescribed Drug Register, NPR and LISA.  
 
STATISTICAL METHODS 
The PCC visit pattern was characterised by PCC mean number of appointments 
with nurses and physicians respectively and breakdown of facilities into two 
QregPV (patient 
selection) 
Vega 
NPR LISA 
Prescribed Drug 
Register 
Appointments, 
diagnoses 
Diagnoses Socioeconomic 
status 
Medications 
Figure 4. Register data for study III. Abbreviations: LISA: Statistics Sweden 
Longitudinal Database; NPR: National Patient Register; QregPV: regional 
primary care register; Vega: regional administrative healthcare database 
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 groups depending on the ratio between appointments to the two professions. 
Nurse-based care was defined as more appointments with nurses than 
physicians. The likelihood that an individual would have BP ≤ 140/90 mmHg 
was assessed depending on visit patterns.  
A multi-level mixed model was used with a dichotomous dependent variable 
at the individual level of whether BP ≤ 140/90 mmHg. PCC was modelled as 
a random factor. The fixed factors were the variables that had been adjusted 
for. Three different adjustment models were used: 1) adjustment for age and 
sex only; 2) model 1 plus BMI, smoking, country of birth, marital status, 
education and number of anti-hypertensive drugs; 3) model 2 plus number of 
individual appointments with a physician or nurse and which professional had 
taken BP. 
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STUDY IV – ADHERENCE TO GUIDELINES 
STUDY RATIONALE 
Financial incentives have been used in VGR since the healthcare reform of 
2009, which included entry of important variables for the care of diagnosed 
CHD. The proportion of patients in this group who attain the LDL-C target is 
approximately 20% [64] despite the recommendations of national and 
international guidelines [57].  
STUDY POPULATION AND PERIOD 
Patients with diagnosed CHD in QregPV on 31 December 2015 were included 
in the study. Additional information at the individual level was added from 
Vega, Prescribed Drug Register, NPR and Cause of Death Register, see Figure 
5. A risk estimation cohort from 2011 with follow-up data for five years was 
used to create a model for the risk of a new CVD event or all-cause mortality.  
 
STATISTICAL METHODS 
A risk prediction model based on Cox proportional hazards regression was 
used. Follow-up data with endpoints - mortality, acute myocardial infarction 
(AMI), stroke - were available until 31 December 2015. The variables included 
in the model were age, sex, diabetes, a history of heart failure and/or atrial 
fibrillations, stroke or AMI over the past year and treatment with 
acetylsalicylic acid. 
QregPV (patient 
selection) 
Vega 
NPR Cause of Death 
Register 
Prescribed Drug 
Register 
Appointments, 
diagnoses 
Diagnoses Dates and causes 
of death 
Medications 
Figure 5. Register data for study IV. Abbreviations: NPR: National Patient 
Register; QregPV: regional primary care register; Vega: regional administrative 
healthcare database 
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 Based on the risk prediction model, the individual risk for a new CVD event 
or death from all causes over five years was estimated for the study cohort. 
Summing up individual risks yielded the total number of individuals who were 
estimated to have experienced an event over 5 years. We performed two 
adjusted predictions and evaluated the effects of: 
• lowering LDL-C to 1.8 mmol/L among patients with higher 
LDL-C 
• administering atorvastatin 40/80 mg to patients with no statin 
treatment or less potent statin therapy and LDL-C > 1.8 
The adjusted predictions were based on published data concerning lowering of 
risk of CVD or death per 1 mmol/L decrease of LDL-C [68, 94]. Risk reduction 
with intensified statin treatment was based on expected LDL-C decrease 
related to the type of statin and dosage from a study designed for that purpose 
[95]. 
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 RESULTS 
STUDY I – P4P AND DATA ENTRY 
After the introduction of a P4P programme in VGR on 1 January 2011, 
inclusion of patients in the register continued its long-term rise. The increase 
occurred in the reference region as well.  
Patterns associated with data entry also changed. The percentage of patients 
with medical variables grew in VGR but not in the reference region, see Table 
2. Entry of LDL-C increased most (17.8%).  
¤Information about HbA1c, BP, LDL-C, albuminuria (yes/no) and smoking (yes/no). Abbreviations: BP: 
blood pressure; HbA1c: glycated haemoglobin; LDL-C: low density lipoprotein cholesterol 
 
Patients and data entered after P4P was introduced differed from those in the 
register already before 2011. New patients had medical variables that were less 
well controlled compared to the patients already in the register. Patients with a 
diabetes diagnosis since at least two years, but first entered in the register in 
2011, had lower treatment intensity and higher mean values of HbA1c, BP and 
LDL-C than those entered also in 2009 or 2010. Patients for whom LDL-C had 
not been entered in 2009-2010 had significantly higher values than those with 
entries for all three years: 2.68 (2.65-2.71) mmol/L vs. 2.56 (2.55-2.58) 
mmol/L. Calculations were adjusted for age, sex and diabetes duration.  
Table 2, Percentage of patients with entry of separate variable for the study and reference region 
in 2010 and 2011. 
 VGR Reference region 
 2010 2011 Change (%) 2010 2011 Change (%) 
N 39268 44785 14.0 26812 32804 22.3 
BP 92.2% 94.5% 2.5 86.8% 85.7% -1.3 
HbA1c 94.4% 95.3% 1.0 93.7% 94.5% 0.9 
LDL -C 70.2% 82.7% 17.8 71.1% 69.7% -1.4 
Albuminuria 84.7% 84.5% -0.2 69.7% 67.1% -2.0 
Smoking 83.4% 91.8% 10.1 86.9% 85.9% -1.2 
Entry of all 5 
variables¤ 
56.7% 71.6% 26.3 46.2% 45.5% -1.5 
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BP entry patterns had changed in VGR, i.e., greater preference for sub-target 
BP and less for round-of values, compared to the reference region see Figure 
6.  
 
The proportion of patients who attained the BP target rose from 23.7% to 
28.0% (p < 0.001) while BP decreased from 134.8/76.7 to 133.8/76.4 mmHg 
(p < 0.001) in VGR: no difference was noted in the reference region, see Table 
3. HbA1c and LDL-C levels were down but there was no significant difference 
between the regions.  
 
 
 
Figure 6. Percentage point change for various subgroups of BP readings in mmHg. 
Abbreviations: DBP: diastolic blood pressure; BP: blood pressure; SBP: systolic blood 
pressure; VGR: Region Västra Götaland 
-6
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Abbreviations: BP: blood pressure; HbA1c: glycated haemoglobin; LDL-C: low density lipoprotein 
cholesterol 
Although the greatest impact of entry was found around the target, patients 
with higher BP were also affected. Patients with poorly controlled systolic BP 
(SBP ≥140) in VGR saw larger decreases than in the reference region (-9.3 vs 
-6.3 mmHg, p < 0.001). 
 
Table 3. HbA1c, BP and LDL-C for patients in the NDR for VGR and the reference region in 
2010 and 2011. 
 VGR Reference county  
Year 2010 2011 2010 2011 p  
diff 2011-2010 
N 39 268 44 785 26 812 32 804  
HbA1c      
    mmol/mol 53.5 (13.2) 52.9 (13.4) 54.1 (13.1) 53.8 (13.5) 0.139 
    <52 (%) 53.5 56.6 51.9  53.4  <0.001 
BP      
   systolic, mmHg 134.8 (15.9) 133.8 (15.7) 135.7 (15.9) 135.6 (15.7) <0.001 
   diastolic, mmHg 76.7 (9.6) 76.4 (9.7) 76.5 (9.5) 76.6 (9.6) <0.001 
    < 130/80 (%) 23.7 28.0 22.3 22.2 <0.001 
LDL-C      
   mmol/L 2.71 (0.89) 2.68 (0.91) 2.68 (0.93) 2.65 (0.94) 0.139 
  < 2.5 (%) 45.4 47.3 47.0 48.3  <0.001 
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STUDY II – P4P AND PROCESS MEASURES 
After the introduction of payment linked to entry of a code for medication 
reviews, the percentage of codes increased rapidly at all PCCs: those that coded 
for many reviews (Group 3), for a few (Group 1) and in between (Group 2), 
see Figure 7. In 2009-2013, the proportion of patients with a code increased 
from 3.2% to 44.1 %. Meanwhile, ACG weight, a measure of disease burden, 
also increased.  
 
 
The percentage of patients with inappropriate drugs and polypharmacy was 
generally lower in Group 3 than in Group 1. The percentage who were 
receiving inappropriate drugs or 10 or more drugs decreased in Group 1 as well 
as in Group 3, see Figure 8. The percentage who had filled prescriptions of 
three or more psychotropic, antipsychotic or non-steroidal anti-inflammatory 
drugs (NSAID) also decreased. Prescriptions for statins, which are not 
considered inappropriate, were included for comparison purposes. 
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Figure 7. Percentage of patients with a medication review code and mean ACG weight in the 
three PCC groups; Group 1 (few), Group 3(many). 
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There were no significant differences in improvement between the groups from 
2009 to 2013 for any of the indicators, see Table 4.  
 
 
Figure 8. Group 1 and 3 over time, percentage of patients taking inappropriate, ten or more, 
three or more psychotropic, antipsychotic, non-steroidal anti-inflammatory (NSAID) drugs or 
statins. The estimates are based on mixed generalised linear models. Group 1 (few), Group 
3(many). 
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 Abbreviations: NSAID: Non-steroidal anti-inflammatory drugs 
 
 
 
Table 4. Estimated ratios for all drug indicators comparing 2013 to 2009 including odds ratios 
for all variables except the number of drugs, for which a simple ratio is used. 
 Group 1 Group 2 Group 3 
Number of drugs 0.80 [0.79, 0.81] 0.82 [0.81, 0.83] 0.81 [0.80, 0.82] 
Inappropriate drugs 0.62 [0.59, 0.65] 0.64 [0.61, 0.67] 0.61 [0.58, 0.64] 
Long acting benzodiazepines 0.57 [0.53, 0.62] 0.60 [0.56, 0.66] 0.56 [0.51, 0.62] 
Drugs with anticholinergic effect 0.71 [0.67, 0.76] 0.74 [0.69, 0.78] 0.73 [0.68, 0.78] 
Propiomazine 0.62 [0.56, 0.68] 0.60 [0.54, 0.66] 0.54 [0.48, 0.60] 
Tramadol 0.55 [0.50, 0.61] 0.56 [0.51, 0.62] 0.55 [0.50, 0.62] 
Ten or more drugs 0.50 [0.47, 0.52] 0.54 [0.51, 0.56] 0.53 [0.50, 0.55] 
Three or more psychotropic drugs 0.61 [0.57, 0.66] 0.65 [0.61, 0.70] 0.64 [0.60, 0.69] 
Antipsychotics 0.55 [0.50, 0.60] 0.62 [0.57, 0.67] 0.54 [0.49, 0.60] 
NSAIDs 0.54 [0.51, 0.58] 0.56 [0.52, 0.60] 0.57 [0.53, 0.61] 
Statins 1.09 [1.05, 1.13] 1.13 [1.10, 1.17] 1.12 [1.08, 1.16] 
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 STUDY III – ORGANISATION – NURSE-BASED 
CARE 
A total of 52 of 188 PCCs in VGR had nurse-based care according to the 
definition of this study, i.e. more appointments with nurses than physicians for 
hypertension. Mean number of appointments at the PCCs varied substantially: 
0 to 2.3 for nurses and 0.4 to 2.8 for physicians. 
Patient characteristics (age, sex, BMI, smoking) did not differ between PCCs 
with nurse-based approaches and others. Patients at nurse-based PCCs had 
somewhat lower mean BP (136.9 vs 137.8 mmHg) and the percentage who 
were being treated properly was higher: BP ≤ 140/90 (64.6% vs. 62.3%) and 
BP ≥ 150 (17.6% vs. 20.1%). More patients had antihypertensive treatment 
(87.8% vs. 85.1%) and the total mean number of appointments was higher (2.7 
vs. 2.4) at nurse-based PCCs. With a fully adjusted model, the chance of having 
a BP ≤ 140/90 was 10% higher at PCCs with nurse-based care than at PCCs 
that had more appointments with physicians, see Figure 9. 
 
 
Figure 9. OR that the patient would attain BP ≤140/90 mmHg: at nurse-based PCCs and with 
an increased mean number of appointments with physicians and nurses respectively at the PCC 
(the OR represents the increased odds with an increase of one in the mean number of 
appointments). Three different adjustment models were used: 1) adjustment for age and sex 
only, 2) model 1 plus BMI, smoking, country of birth, marital status, education and number of 
anti-hypertensive drugs, 3) model 2 plus number of individual appointments with a physician 
or nurse and whether BP had been taken by a physician or nurse. 
Nurse-based care OR (95% CI)
  model 1 1.12 (1.02 to 1.22)
  model 2 1.11 (1.02 to 1.22)
  model 3 1.10 (1.01 to 1.21)
Physician appointments
  model 1 0.95 (0.84 to 1.06)
  model 2 0.95 (0.84 to 1.07)
  model 3 1.00 (0.89 to 1.13)
Nurse appointments
  model 1 1.07 (0.99 to 1.15)
  model 2 1.07 (1.00 to 1.15)
  model 3 1.08 (1.01 to 1.16)
0,7 0,8 0,9 1 1,1 1,2 1,3
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 There was a tendency towards higher chance of attaining the BP target with a 
larger ratio at the PCC between appointments with nurses and physicians, see 
Figure 10. 
Figure 10. OR that a patient would attain BP ≤140/90 mmHg with a greater nurse/physician 
appointment ratio at the PCC (nurse-based care is defined as a ratio > 1). Calculations were 
based on model 3: adjustment for age, sex, BMI, smoking, country of birth, marital status, 
education, number of anti-hypertensive drugs, number of individual appointments with a 
physician or nurse and whether BP had been taken by a physician or nurse. 
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 STUDY IV – ADHERENCE TO GUIDELINES 
A total of 18% of a secondary preventive population of 37,120 patients with 
previous CHD attained the high-risk LDL-C target (≤1.8 mmol/L). The mean 
LDL-C was 2.7 mmol/L and 32% were not receiving any statin treatment. 
Among the non-controlled patients, whose LDL-C was > 1.8 mmol/L, an 
average reduction of 1.2 mmol/L (40%) was required to reach the target. Statin 
treatment was most common (70%) for age 50-75. Prescriptions filled declined 
rapidly after the age of 80.  
If all patients received atorvastatin 80 mg, the mean LDL-C would presumably 
decrease from 2.7 to 1.9 mmol/L overall and from 3.0 to 2.0 mmol/L for all 
non-controls (LDL-C >1.8 mmol/L). 
Based on individual risks, the estimated number of CVD events over 5 years 
was 9,209/37,120 (24.8%).  If all patients who were receiving no or less 
intensive statin treatment were given atorvastatin 80 mg, a reduction of CVD 
events by 14.2% (7,901 vs 9,209) was predicted. If all patients attained LDL-
C ≤1.8 mmol/L the predicted number of events would be reduced by 17.7% 
(7,577 vs 9,209). If all patients were prescribed 80 mg atorvastatin, the 
predicted proportion who experienced a CVD event would be reduced by 
32.9% (967) among non-statin users and 5.4% (339) among users. 
Assuming the same risk throughout the study population, including those 
without an LDL-C entry (n = 57,341), the potential reduction in number of 
CVD events among patients with CHD over 5 years with atorvastatin 80 mg 
would be over 2,000.  
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 DISCUSSION 
The primary care reform in VGR accelerated the change in attitude about 
evaluation and follow-up of healthcare performance. The transition that had 
begun in specialised care with Open Comparisons (Öppna jämförelser) now 
culminated for primary care. Inclusion of both privately and publicly owned 
PCCs demanded new methods of data collection; a register-based quality 
initiative was launched.   
The focus of this thesis was financing and follow-up as well as potential areas 
for improvement among major groups of patients. Financial incentives, the 
effect of organisation on quality of care and the gap between clinical practice 
and guidelines were studied.   
RESULTS DISCUSSION 
P4P AND DATA ENTRY 
The entry of patients in the NDR has been one of the most common indicators 
for regional primary care P4P programmes. The performance target was 
initially used by 9 out of 21 regions [35]. The design of the P4P programme in 
VGR, however, was unique in that the entry of separate variables and medical 
targets were also reimbursed.  
Study I found significant and clinically relevant changes in entry behaviour 
after the adoption of a detailed P4P programme. Coverage and completeness 
of data both increased.  
In both VGR and the reference region, entry of patients was reimbursed, and 
inclusion increased, in the NDR. Entry of separate variables was reimbursed 
in VGR only where it increased compared to the reference region. The impact 
on entries in VGR after the introduction of payment linked to diagnoses also 
boosted entry of chronic conditions, which qualify for higher reimbursement 
than minor health problems [96]. Increased register entry linked to financial 
incentives confirms the results of previous studies [38, 39, 50, 52, 97-99].  
Patients entered after the start of the P4P programme were not as well-
controlled with regard to HbA1c, BP or LDL-C as those who were already 
registered before. Individual variables that had been missing before were not 
as well-controlled as already included data either. Similar results have been 
described for other Nordic registers [34, 100]. These results show that data 
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were not missing at random and that low coverage and missing data pose a risk 
of overestimating performance. This can also lead to misinterpretations in both 
research and public comparisons [18, 33].  
In other words, reimbursement boosts data entry but incentives linked to 
medical targets may also change entry behaviour. An increased preference for 
entry of BP values just below the target of <130/80 mmHg was accompanied 
by an 18% increase in patients who attained it. A greater preference for BP 
values just below target has been described earlier [101, 102]. In addition to 
the effect around target, there was also a decrease in systolic BP in patients 
with BPs in the higher range (systolic BP >140) in VGR not seen in the 
reference region. The greater percentage of patients who attained the specific 
target was probably a round-off effect that does not explain the decline in mean 
systolic BP. One possible explanation is that reimbursement sharpened the 
focus on BP and antihypertensive treatment. We did not investigate whether 
PCCs that benefited from the incentive programme showed reduced BP or 
simply fewer round-off values.  
When payment for entry of patients in a register is combined with that for 
separate medical variables, data become more complete and useful. But paying 
merely for inclusion of a patient is hardly meaningful since it results in missing 
data that can cause performance to be overestimated. Reimbursement linked to 
variables, such as BP, that are prone to bias, may alter data entry behaviour 
and compromise comparability of data.  
P4P AND PROCESS MEASURES 
The search for relevant measures that can track follow-up of care among the 
elderly and other primary care patients has led to an innovative but 
questionable design of indicators. The KVÅ codes for these measures are used 
for control and reward rather than clinical purposes, see Figure 11 for 
examples. This contrasts with diagnostic coding, since such conditions are 
familiar to the physician and form the basis for decisions concerning treatment 
and follow-up. The KVÅ codes used in primary care are often accompanied by 
long descriptions of details about their criteria as opposed to easily identifiable 
follow-up measures like electrocardiogram (ECG) and surgical procedures. 
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Study II looked at financial incentives linked to a KVÅ code for medication 
reviews, a process measure. The number of patients for whom a code was 
entered increased rapidly after the introduction of financial compensation, 
albeit with a large variation between PCCs. Prescriptions improved among the 
PCCs with the lowest payment for coding of medication reviews as much as 
among those with the highest payment. No significant differences in 
improvement over five years was detected between the two groups of PCCs. 
The results of the study do not show a clear relationship between indicator and 
outcome, i.e., between a high proportion of patients with a KVÅ code and 
better pharmacological treatment of the elderly.  
Process measures have been described as more sensitive to financial incentives 
than outcome measures [51, 103, 104]. For an improvement in a process 
measure to be of clinical importance, a direct association between the indicator 
and desired outcome is needed. This is rarely the case for healthcare process 
measures [47, 105]. There is a risk that the coding target will be reached but 
not the effect (better medical treatment) [48, 106]. Evidence for medication 
reviews as a means of reducing hospitalisation and death is also lacking [107-
110]. Coding for process measures with a weak association between the 
indicator and outcome is of doubtful value, “hitting the target but missing the 
point” is a known problem with process indicators [47].  
Our results show that not even a clearly defined KVÅ code is likely to be 
meaningful for follow-up of primary care quality. The financial incentive was 
followed by adjusted behaviour and an increase in the number of medication 
reviews entered but not better medical treatment. For several other KVÅ codes 
used in primary care there is no apparent association between the indicator and 
Figure 11. Examples of ICD and KVÅ codes used in VGR 
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outcome. This type of incentive carries the risk of measuring and reimbursing 
adaptation to an incentive programme instead of health-related results. The 
focus is on quantity rather than quality and the incentive becomes similar to 
fee-for-service. 
ORGANISATION – NURSE-BASED CARE 
Due to the extent of regional administrative and medical data, organisational 
measures can also be evaluated. PCC level characteristics can be related to 
outcomes for individual patients after controlling for personal characteristics. 
The focus of study III is on hypertension, the largest diagnostic group in 
primary care, all of whom are at risk of serious complications unless treated 
properly.  
Study III examined real-world visit data. Nurse-based care, as a part of PCC 
enrolment, was associated with better BP control in cases of uncomplicated 
hypertension. Although earlier published data and European guidelines point 
out the benefits of nurse-based care, major variations were found among the 
PCCs in terms of both mean numbers of appointments and the ratio between 
those with nurses and physicians. The higher the percentage of appointments 
with nurses at the PCC, the greater the likelihood that the BP target would be 
attained for individual patients. These findings are consistent with previous 
studies which have concluded that team-based care and other quality 
improvement strategies that transfer part of the responsibility to non-
physicians, are effective [54, 93]. Team-based care that transfers tasks from 
physicians to nurses as used in many countries has proven to be at least as 
effective as standard approaches [54, 59-61, 111].  
Target variation in BP control is certainly more patient than PCC-related but 
PCC factors including nurse-based care is also part of the equation. The large 
patient population is growing and even a small contribution to better control 
should have a clinically important impact on the ability to mitigate the 
consequences of hypertension. Modest reduction of BP at the population level 
has been shown to be efficient in limiting CVD events [112, 113].  
Many of the financial incentives are directed at care and risk factor 
management of hypertension, CHD and other long-term conditions. The 
growing number of patients with chronic disease places greater demands on 
healthcare services. Nevertheless, adherence to guidelines is still 
unsatisfactory. PCCs in VGR are required to have specially trained nurses for 
diabetes and COPD but not for cardiovascular conditions. Nurse-based care 
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 and other organisational variables have an untapped potential and should be 
considered when structuring approaches to chronic disease.  
ADHERENCE TO GUIDELINES 
Adherence to guidelines for care of chronic disease has been addressed in a 
number of ways. But a significant percentage of patients are still not attaining 
targets for diabetes, hypertension, CHD and other long-term conditions. 
Financial incentives linked to medical targets were not used for CHD cases 
during the study period. Payment was nevertheless linked to entry of LDL-C. 
P4P linked to LDL-C and BP targets for patients with CHD was introduced in 
2016 but eliminated in 2017 [114]. European guidelines concerning the target 
for LDL-C among very high-risk patients have been the same (< 1.8 mmol/L) 
since 2011 in [115]. 
The results of study IV show that two-thirds of a primary care population with 
established CHD were receiving statin treatment and only a minority were 
attaining treatment goals for LDL-C. An improvement in that regard could 
spare many patients a new CVD event in 5 years. The greatest potential was 
seen among patients who are not currently receiving statin treatment. A recent 
Swedish study explored short-term adherence to statins and the possible impact 
on CVD events among 5,904 post-AMI patients [116]. The study projected a 
15% (132-343 patients) reduction in the number of events over 10 years if 
LDL-C is lowered to 1.8 mmol/L. The patients were younger and the treatment 
gap narrower than in our study. 
Short-term adherence to lipid-lowering treatment after AMI has gradually 
improved in Sweden to approximately 90% [117]. Adherence to statin 
treatment among the primary care study population was 68% and only a small 
percentage had an event over the past year. One reason for the discrepancy may 
be that adherence declines with time [118]. A delay in the adoption of new 
primary care guidelines for patients whose last event occurred many years 
earlier is also likely. Scepticism about treating the elderly with statins due to 
fear of adverse effects and expectations of only minor benefits may also come 
into play. In recent years, statin treatment has been proven to be safe and 
effective for the aged as well [69]. We found that the percentage receiving 
statin treatment diminishes substantially after 75 corroborating another 
Swedish study of patients with previous CVD [119].  
The potential for avoiding new CVD events if guidelines concerning lipid-
lowering treatment were followed more closely appears to be substantial. 
Greater awareness among both physicians and patients is needed if adherence 
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is to improve. Besides knowledge, physicians need appropriate organisational 
conditions. Structures that facilitate follow-up of these patients such as team-
based care, would presumably boost patient and physician adherence.  
METHODOLOGICAL CONSIDERATIONS – 
STRENGTHS AND LIMITATIONS 
Depending on the research issue, the study design, setting, group breakdown 
and choice of analysis should always be questioned. Designs and methods were 
chosen on basis of relevance and feasibility.  
All studies were observational and register-based as opposed to RCTs, limiting 
the ability to make causal interpretations. Nevertheless, the large number of 
patients is a major advantage and the data reflect clinical settings unaffected 
by research protocols. The patient population for RCTs is often strictly 
selected. STrengthening the Reporting of OBservational studies in 
Epidemiology  (STROBE ) is an international initiative that generates 
checklists to improve quality [120].  We tried to follow those criteria.  
The inclusion of so many patients requires register data, which restricts the 
number of available variables. The studies could have been supplemented by 
information about PCC level based on regional or survey data from their staffs. 
Such data may though be incomplete and incorrect due to low response 
frequency and recall problems.  
The overall aim of this thesis was to perform a register-based evaluation 
regarding certain aspects of primary care chronic disease management 
following the reform. The questions arose from problems and experiences 
associated with everyday practice as well as observations derived from 
aggregate data. Thus, no designs other than register-based observational 
studies were considered.  
Most research questions are amenable to alternative approaches. There is no 
inherent conflict between register-based and other studies. The various 
approaches complement each other. Register-based studies proceed from a 
large number of patients and comparatively few variables. Related issues can 
be addressed by studies based on electronic health record reviews, 
questionnaires, interviews with patients, staff and administrators or qualitative 
study designs. Such results proceed from comparatively few patients and much 
more extensive data for each one. An RCT is also an option when looking at 
organisational factors such as nurse-based care [61].  
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 Another reason for the register-based approach we used is that the results 
emerge from and are useful in clinical every-day practice. The findings can be 
conveyed directly to those who perform and govern care by showing that 
quality improvement matters.  
STUDY DESIGN AND SETTING 
The regional perspective, including public funding from the same source 
regardless of who owns the PCC and almost complete register coverage, is a 
major strength of this thesis. Because the majority of patients with chronic 
disease are in primary care, it is important that research be performed in that 
setting. Real life circumstances also pose problems. When examining the 
introduction of reforms and the like, it is difficult to know whether the effect 
is due to the intervention or surrounding factors [12]. Study I partly overcame 
this obstacle by means of comparisons with a reference region. Due to the large 
variation in coding behaviour among the PCCs in the region and the fact that 
they were all subject to the same reimbursement, Study II could compare 
groups of them. Because of regional differences in terms of entry and 
reimbursement, a reference region was not feasible.  
Studies I and II were repeated cross-sectional instead of longitudinal so as to 
include as many patients as possible at each point in time. With a longitudinal 
design, changes over time could have been analysed at an individual rather 
than aggregate level. But such a design would have missed patients who were 
first entered in the register between two points in time. Study I shows that 
missing patients are a potential problem if new ones differ from old ones. 
The various registers - NDR in Study I, Vega in Study II and QregPV in 
Studies III and IV - were the basis for selection. Patient coverage is very high 
in these registers. QregPV uses automated monthly data extraction from 
electronic health records at PCCs for all patients with the specified diagnoses 
[63]. Data extraction for Vega is also automated and is used for financial 
reimbursement in the region. NDR coverage increased in 2008 – 2011 from 
approximately 60% to 90% and is now almost complete [121]. Coverage in the 
reference region was approximately 85% in 2011 as opposed to 96% in VGR 
[79]; more of the reporting was manual (38% vs 31 % according to NDR 
sources). Study I may have missed patients given that reporting to the NDR is 
mandatory for neither them nor the provider. Since reporting of data about 
diabetes cases for regional follow-up is mandatory, the NDR is used by all 
PCCs in VGR and coverage is high.  
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The prediction model in Study IV was based on the literature concerning 
expected LDL-C reductions in relation to statin type and dosage [95]. This 
reference is cited in the Swedish Book of Medicines (Läkemedelsboken) and 
British NICE guidelines [122]. A combined risk reduction for CVD (AMI and 
stroke) per 1 mmol/L decrease in LDL-C was used, because the figures for the 
outcome of stroke differed substantially among subgroups of studies and there 
was no combined measure for all of them [68]. Nor was there a combined 
measure for the outcome of AMI and the risk reduction was greater than for 
CVD such that our calculations were conservative in that regard.  
MISSING DATA 
The thesis was based on data from registers with greatly differing rates of 
missing data. Apart from in Study I, data from several registers and health 
databases were linked by means of personal identity number. Population-based 
health data registers are complete and do not suffer from any selection bias 
[123]. The NPR has virtually full coverage [85]. The data concerning 
prescriptions filled in the Prescribed Drug Register has very high coverage 
given that retrieval is automated and generated by administrative systems 
[124]. Coverage in the Cause of Death Register is also complete [125]. The 
time of death is recorded regardless of whether a cause has been reported. LISA 
and the Population Register have full coverage. Missing data are common in 
the NDR and QregPV for certain variables and have been handled variously in 
Studies I, III and IV. Missing data always pose a risk of bias but the 
magnitude is difficult to assess.  
Missing data were not replaced in Study I since the associated variables were 
outcomes (HbA1c, BP, LDL-C). To include as many patients as possible, 
complete case analysis was not used and everyone for whom data about crucial 
variables were available appeared. As an example, patients for whom BP was 
entered but LDL-C missing were included in the calculations for the former 
variable but not the latter. Use of a complete case strategy would have 
substantially reduced the number of patients included and compromised the 
ability to draw meaningful conclusions. 
Study II collected data from registers with total coverage, including age and 
sex. Patients for whom no entries had been made concerning diagnosis or 
prescriptions filled were presumed not to have the diagnosis or medications. 
Study III had missing data regarding smoking and BMI; because these 
variables were used as covariates (not exposures or outcomes) they were 
imputed so that the analyses could include all patients. Sensitivity analyses 
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 (testing for robustness) showed no differences between imputed data and 
complete case analyses.  
Study IV had a great deal of missing data in both 2011 and 2015. The variables 
for which the most data were missing was smoking (79% in 2011, 26% in 
2015), BMI (65% in 2011, 25% in 2015) and LDL-C (68% in 2011, 35% in 
2015). Given the large quantity of missing data, it was inappropriate to use 
imputation. Risk estimations without BMI and smoking were performed even 
though they are known to be linked to CVD. Sensitivity analyses of complete 
cases with and without these variables did not change the percentage decrease 
for the number of predicted events. The extent of the missing for LDL-C in 
2015 reduced the number of patients with the prediction of a new event and 
there was no reason to believe that those excluded faced a smaller risk. On the 
contrary, they were older and less likely to be receiving statin treatment. While 
assessing LDL-C on an annual basis may not always be necessary, data were 
obtained up to 900 days before the index date. The results of Study I, although 
for patients with diabetes, suggested that those for whom no values have been 
entered tend to have higher LDL-C levels. 
CONFOUNDING 
False results may be an effect of confounding, a problem that is particularly 
common in observational studies. Uncontrolled confounding may lead to false 
conclusions. Age and sex are easy to control for by using them as covariates, 
as was done in all the studies.  
Study I also included diabetes duration since it is an important component of 
risk factor evaluation. Comorbidity is also a major source of confounding. 
Statistical efforts to control for comorbidity are dependent on the extent to 
which conditions are known and properly described in the registers. We could 
have included information on comorbidity and medication in Study I but had 
no reason to suspect that patients in two of the largest Swedish regions would 
differ. Nor were the entry effects likely to be affected, given that the incentives 
should be insensitive to them. 
Consideration of disease burden is vital in Study II because it is associated 
with medication. ACG weight, a composite measure of disease burden was 
used instead of ICD-codes. However, the weight might not accurately reflect 
individual disease burden given that ACG reporting was also financially 
rewarded during the study period. If PCCs with a high level of medication 
review coding were more prone to report diagnoses, that form the basis of ACG 
calculations, the percentage of patients with inappropriate drug use would 
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appear to be lower for high coding PCCs due to statistical adjustment. As a 
result, differences between the groups would be overstated. Changes in drug 
treatment over time, rather than absolute levels, represented the main source 
of comparison in Study II. Prescriptions filled, independent of diagnostic 
coding, were also highly informative. Statin prescriptions were similar in all 
three groups despite variations in ACG weight, suggesting that CVD burden 
did not differ significantly between high and low coding PCCs.   
Study III minimised the impact of comorbidity by excluding patients with a 
significant problem in that respect. PCCs rather than individuals were studied 
where uncontrolled confounding would have had a larger impact due to the 
association between concomitant disease (coded or not) and visit patterns. 
Appointments, socioeconomic and other individual factors were added to the 
various adjustment models. Socioeconomic factors as well as BMI and 
smoking, no doubt differed among the PCCs. However, the results did not vary 
significantly, regardless of the model chosen. 
Study IV did not examine the effect of exposure on an outcome. Estimates for 
the effect of lipid-lowering treatment or LDL-C reduction were taken from 
meta-analyses such that unknown confounding should not be a significant 
problem.  
STATISTICAL CONSIDERATIONS 
The choice of statistical methods is a balancing act between absolute 
correctness and robustness, comprehensibility and communicability. Statistical 
methods most pertinent to the specific aims were used, while analysis was 
simple but statistically sound.  
Study I assessed the difference between regions with respect to improvement 
from 2010 to 2011 including only patients who had been entered for both years. 
This was in order to perform the tests for significance for the change over time 
based on individual data. The obvious disadvantage was the exclusion of new 
individuals. Given that data were reported for all patients, this limitation was 
not considered a problem. 
Studies II and III grouped PCCs as primary explanatory variables. PCC 
characteristics - the percentage of patients with a code for medication review 
(Study II) and the percentage of appointments with nurses for hypertension 
care (study III) were used for grouping variables. An underlying continuous 
variable was categorised such that information was lost but interpretability 
enhanced. Without categories, higher or lower odds of should be assessed in 
the light of a one-step increase in the continuous variable. Thus, 
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 comprehensible groups facilitate determination of the clinical relevance of 
findings.  The number of groups and the associated cut-off values were 
arbitrarily chosen. The use of only two groups would make it more difficult to 
demonstrate a difference. The more groups, the fewer patients in each one and 
the less stable the results. Study II broke the PCCs down into three groups of 
equal size. Study III relied on two groups depending on whether physician or 
nurse appointments were predominant. 
A mixed model is one way of handling observations that are not independent 
by means of various levels of abstraction. Other statistically less complex 
approaches are the analysis of subgroups, aggregation, change scores and 
dummy variables, though at the expense of less information and problems with 
missing data. Study II analysed repeated data concerning individual 
medications and Study III looked at patients across PCCs. Patients and PCC 
were treated as random factors while the induced variation but not the specific 
impact on outcome was taken into account. A compound symmetry covariance 
(exchangeable) matrix captured the correlation between observations of the 
same patient (Study II) and PCC (Study III). All variances are the same in 
such a matrix, assuming a constant difference between measurements. Study 
II could have used an autoregressive structure for which observations that 
happen around the same time are more highly correlated. Medications were, 
however, presumed to be fairly stable over time and it is not certain that 
measurements far away in time have a small correlation. Correlations between 
patients at a particular PCC were not hypothesised as differing in any specific 
way. If a fixed effects model were used rather than a mixed one, the level of 
the effect would be similar but the confidence intervals narrower. A mixed 
model compromises precision when the degrees of freedom decreases. Study 
II could also have used PCC as a random factor since exposure was at that 
level. 
Studies II, III and IV obtained data about prescriptions filled from the 
Prescribed Drug Register. Study II took a more elaborate approach to 
analysing medication data. To more accurately estimate drug exposure on a 
particular date, consideration was paid to both quantity and dosage [91]. 
Studies III and IV considered a prescription filled within 120 days to be a 
treatment regardless of amount and dosage. Drugs are prescribed in Sweden 
for up to 90 days but refills often occur earlier. This approach may overstate 
the case since having filled one prescription does not necessarily mean that 
treatment is ongoing. Both approaches reveal whether the patient has filled a 
prescription but not subsequent adherence.  
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Study IV used survival analysis with Cox proportional hazards regression. The 
main event of interest was CVD with death as a potentially competing event. 
We proceeded from effects on cardiovascular complications by reduction of 
LDL-C or more intensive lipid-lowering treatment as reported in the literature 
[68, 94]. Virtually all articles cite hazard or risk ratios that are unsuitable for a 
model of competing risks, which instead rely on sub-distribution hazard ratios. 
Cox proportional hazards regression without competing risks can be used when 
it is reasonable to study the cumulative incidence of an event on the 
presumption of survival. But the cumulative incidence of events is affected by 
death, which was not taken into consideration. The total number of events is 
certainly somewhat smaller than the results indicate but the relative decrease 
was not necessarily affected.  
LDL-C, especially among the oldest patients was missing to some extent in 
Study IV. The likely explanations are general frailty or the continued impact 
of earlier guidelines that recommended against treating hyperlipidaemia in this 
age group. As a result, the potential of statin treatment to reduce morbidity was 
probably understated.  
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 CONCLUSIONS 
Regional register data used after the primary care reform to follow up on the 
care of chronic disease is an important source of information for in-depth 
analyses. Available data can be used to evaluate findings for groups of patients 
as well as issues related to PCC organisation and clinical practice.  
The findings of the studies covered by this thesis showed that: 
• Payment linked to entry of patients and data can lead to more 
complete, useful and reliable information.  
 
• Payment linked to coding for specific and complex 
interventions for monitoring and follow-up purposes may 
improve record keeping but not necessarily the intended 
effect. 
 
• Recommendations and guidelines for the structure of care and 
for secondary prevention are not always followed, 
representing potential for better medical results. 
Analyses of regional register data can raise awareness about the impact of 
regulating care and clinical practice. The findings should be considered by 
healthcare authorities and in local quality improvement efforts.  
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IMPLICATIONS AND FUTURE 
PERSPECTIVES 
Due to current legislation, the regional level will form the basis of primary care 
analysis for the foreseeable future. In other words, it is vital to examine 
regional initiatives. 
The availability of data has strengthened the demand for transparency among 
both policymakers and the general public. Since open comparisons hold such 
intuitive appeal, the potential problems must be emphasised more. Otherwise 
healthcare may be propelled in the wrong direction by illusions of 
transparency.  
If financial incentives are used to improve quality, the consequences of 
selected strategies and indicators must be examined to avoid burdensome 
administrative tasks and false starts. Auditing cannot become more important 
than care itself.  
Rising demand for comparisons and strategies for improved primary care 
quality must be met by resources to analyse the prerequisites of meaningful 
action. 
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